APO Research
Talk to an analyst

APO RESEARCH · REPORT

NK-1 Receptor Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global NK-1 Receptor Antagonists Market Analysis and Forecast 2026-2032

29 December 2025208 pages

Choose your research edition.

Industry ResearchNK-1 Receptor Antagonists Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal NK-1 Receptor Antagonists Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal NK-1 Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NK-1 Receptor Antagonists Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal NK-1 Receptor Antagonists Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global NK-1 Receptor Antagonists market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of NK-1 Receptor Antagonists include Dr. Reddy's Laboratories, Eugia Pharma, Fresenius Kabi, Glenmark, Helsinn Healthcare, Heron Therapeutics, Lupin, MSN and Mylan, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for NK-1 Receptor Antagonists, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of NK-1 Receptor Antagonists, also provides the sales of main regions and countries. Of the upcoming market potential for NK-1 Receptor Antagonists, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the NK-1 Receptor Antagonists sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global NK-1 Receptor Antagonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for NK-1 Receptor Antagonists sales, projected growth trends, production technology, application and end-user industry.

NK-1 Receptor Antagonists Segment by Company

Dr. Reddy's Laboratories

Eugia Pharma

Fresenius Kabi

Glenmark

Helsinn Healthcare

Heron Therapeutics

Lupin

MSN

Mylan

Steriscience

TerSera Therapeutics

Teva

Torrent Pharmaceuticals

Beijing Sihuan Pharmaceutical

Hansoh Pharma

Merck

Qilu Pharmaceutical

Sandoz

Yichang Humanwell Pharmaceutical

Chia Tai Tianqing Pharmaceutical

NK-1 Receptor Antagonists Segment by Type

Netupitant

Maropitant

Rolapitant

Fosaprepitant

Aprepitant

Other

NK-1 Receptor Antagonists Segment by Application

Chemotherapy-induced Nausea and Vomiting (CINV)

Postoperative Nausea and Vomiting (PONV)

Other

NK-1 Receptor Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK-1 Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NK-1 Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK-1 Receptor Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of NK-1 Receptor Antagonists in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of NK-1 Receptor Antagonists manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, NK-1 Receptor Antagonists sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global NK-1 Receptor Antagonists Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Netupitant Major Manufacturers Table 3. Maropitant Major Manufacturers Table 4. Rolapitant Major Manufacturers Table 5. Fosaprepitant Major Manufacturers Table 6. Aprepitant Major Manufacturers Table 7. Other Major Manufacturers Table 8. Global NK-1 Receptor Antagonists Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Chemotherapy-induced Nausea and Vomiting (CINV) Major Manufacturers Table 10. Postoperative Nausea and Vomiting (PONV) Major Manufacturers Table 11. Other Major Manufacturers Table 12. NK-1 Receptor Antagonists Industry Trends Table 13. NK-1 Receptor Antagonists Industry Drivers Table 14. NK-1 Receptor Antagonists Industry Opportunities and Challenges Table 15. NK-1 Receptor Antagonists Industry Restraints Table 16. Global NK-1 Receptor Antagonists Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global NK-1 Receptor Antagonists Revenue by Region (2021-2026) & (US$ Million) Table 18. Global NK-1 Receptor Antagonists Revenue by Region (2027-2032) & (US$ Million) Table 19. Global NK-1 Receptor Antagonists Revenue Market Share by Region (2021-2026) Table 20. Global NK-1 Receptor Antagonists Revenue Market Share by Region (2027-2032) Table 21. Global NK-1 Receptor Antagonists Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 22. Global NK-1 Receptor Antagonists Sales by Region (2021-2026) & (K Units) Table 23. Global NK-1 Receptor Antagonists Sales by Region (2027-2032) & (K Units) Table 24. Global NK-1 Receptor Antagonists Sales Market Share by Region (2021-2026) Table 25. Global NK-1 Receptor Antagonists Sales Market Share by Region (2027-2032) Table 26. Global NK-1 Receptor Antagonists Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global NK-1 Receptor Antagonists Revenue Market Share by Manufacturers (2021-2026) Table 28. Global NK-1 Receptor Antagonists Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global NK-1 Receptor Antagonists Sales Market Share by Manufacturers (2021-2026) Table 30. Global NK-1 Receptor Antagonists Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global NK-1 Receptor Antagonists Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global NK-1 Receptor Antagonists Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global NK-1 Receptor Antagonists Manufacturers, Product Type & Application Table 34. Global NK-1 Receptor Antagonists Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global NK-1 Receptor Antagonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global NK-1 Receptor Antagonists Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global NK-1 Receptor Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 39. Global NK-1 Receptor Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 40. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2021-2026) Table 41. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2027-2032) Table 42. Global NK-1 Receptor Antagonists Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 43. Global NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units) Table 44. Global NK-1 Receptor Antagonists Sales by Type (2027-2032) & (K Units) Table 45. Global NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026) Table 46. Global NK-1 Receptor Antagonists Sales Market Share by Type (2027-2032) Table 47. Global NK-1 Receptor Antagonists Price by Type (2021-2026) & (US$/Unit) Table 48. Global NK-1 Receptor Antagonists Price by Type (2027-2032) & (US$/Unit) Table 49. Global NK-1 Receptor Antagonists Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global NK-1 Receptor Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 51. Global NK-1 Receptor Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 52. Global NK-1 Receptor Antagonists Revenue Market Share by Application (2021-2026) Table 53. Global NK-1 Receptor Antagonists Revenue Market Share by Application (2027-2032) Table 54. Global NK-1 Receptor Antagonists Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 55. Global NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units) Table 56. Global NK-1 Receptor Antagonists Sales by Application (2027-2032) & (K Units) Table 57. Global NK-1 Receptor Antagonists Sales Market Share by Application (2021-2026) Table 58. Global NK-1 Receptor Antagonists Sales Market Share by Application (2027-2032) Table 59. Global NK-1 Receptor Antagonists Price by Application (2021-2026) & (US$/Unit) Table 60. Global NK-1 Receptor Antagonists Price by Application (2027-2032) & (US$/Unit) Table 61. Dr. Reddy's Laboratories Company Information Table 62. Dr. Reddy's Laboratories Business Overview Table 63. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolio Table 65. Dr. Reddy's Laboratories Recent Development Table 66. Eugia Pharma Company Information Table 67. Eugia Pharma Business Overview Table 68. Eugia Pharma NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Eugia Pharma NK-1 Receptor Antagonists Product Portfolio Table 70. Eugia Pharma Recent Development Table 71. Fresenius Kabi Company Information Table 72. Fresenius Kabi Business Overview Table 73. Fresenius Kabi NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Fresenius Kabi NK-1 Receptor Antagonists Product Portfolio Table 75. Fresenius Kabi Recent Development Table 76. Glenmark Company Information Table 77. Glenmark Business Overview Table 78. Glenmark NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Glenmark NK-1 Receptor Antagonists Product Portfolio Table 80. Glenmark Recent Development Table 81. Helsinn Healthcare Company Information Table 82. Helsinn Healthcare Business Overview Table 83. Helsinn Healthcare NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolio Table 85. Helsinn Healthcare Recent Development Table 86. Heron Therapeutics Company Information Table 87. Heron Therapeutics Business Overview Table 88. Heron Therapeutics NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Heron Therapeutics NK-1 Receptor Antagonists Product Portfolio Table 90. Heron Therapeutics Recent Development Table 91. Lupin Company Information Table 92. Lupin Business Overview Table 93. Lupin NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Lupin NK-1 Receptor Antagonists Product Portfolio Table 95. Lupin Recent Development Table 96. MSN Company Information Table 97. MSN Business Overview Table 98. MSN NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. MSN NK-1 Receptor Antagonists Product Portfolio Table 100. MSN Recent Development Table 101. Mylan Company Information Table 102. Mylan Business Overview Table 103. Mylan NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Mylan NK-1 Receptor Antagonists Product Portfolio Table 105. Mylan Recent Development Table 106. Steriscience Company Information Table 107. Steriscience Business Overview Table 108. Steriscience NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Steriscience NK-1 Receptor Antagonists Product Portfolio Table 110. Steriscience Recent Development Table 111. TerSera Therapeutics Company Information Table 112. TerSera Therapeutics Business Overview Table 113. TerSera Therapeutics NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolio Table 115. TerSera Therapeutics Recent Development Table 116. Teva Company Information Table 117. Teva Business Overview Table 118. Teva NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Teva NK-1 Receptor Antagonists Product Portfolio Table 120. Teva Recent Development Table 121. Torrent Pharmaceuticals Company Information Table 122. Torrent Pharmaceuticals Business Overview Table 123. Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolio Table 125. Torrent Pharmaceuticals Recent Development Table 126. Beijing Sihuan Pharmaceutical Company Information Table 127. Beijing Sihuan Pharmaceutical Business Overview Table 128. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 130. Beijing Sihuan Pharmaceutical Recent Development Table 131. Hansoh Pharma Company Information Table 132. Hansoh Pharma Business Overview Table 133. Hansoh Pharma NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Hansoh Pharma NK-1 Receptor Antagonists Product Portfolio Table 135. Hansoh Pharma Recent Development Table 136. Merck Company Information Table 137. Merck Business Overview Table 138. Merck NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Merck NK-1 Receptor Antagonists Product Portfolio Table 140. Merck Recent Development Table 141. Qilu Pharmaceutical Company Information Table 142. Qilu Pharmaceutical Business Overview Table 143. Qilu Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 145. Qilu Pharmaceutical Recent Development Table 146. Sandoz Company Information Table 147. Sandoz Business Overview Table 148. Sandoz NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Sandoz NK-1 Receptor Antagonists Product Portfolio Table 150. Sandoz Recent Development Table 151. Yichang Humanwell Pharmaceutical Company Information Table 152. Yichang Humanwell Pharmaceutical Business Overview Table 153. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 155. Yichang Humanwell Pharmaceutical Recent Development Table 156. Chia Tai Tianqing Pharmaceutical Company Information Table 157. Chia Tai Tianqing Pharmaceutical Business Overview Table 158. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 160. Chia Tai Tianqing Pharmaceutical Recent Development Table 161. North America NK-1 Receptor Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 162. North America NK-1 Receptor Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 163. North America NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units) Table 164. North America NK-1 Receptor Antagonists Sales by Type (2027-2032) & (K Units) Table 165. North America NK-1 Receptor Antagonists Sales Price by Type (2021-2026) & (US$/Unit) Table 166. North America NK-1 Receptor Antagonists Sales Price by Type (2027-2032) & (US$/Unit) Table 167. North America NK-1 Receptor Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 168. North America NK-1 Receptor Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 169. North America NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units) Table 170. North America NK-1 Receptor Antagonists Sales by Application (2027-2032) & (K Units) Table 171. North America NK-1 Receptor Antagonists Sales Price by Application (2021-2026) & (US$/Unit) Table 172. North America NK-1 Receptor Antagonists Sales Price by Application (2027-2032) & (US$/Unit) Table 173. North America NK-1 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 174. North America NK-1 Receptor Antagonists Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 175. North America NK-1 Receptor Antagonists Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 176. North America NK-1 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 177. North America NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units) Table 178. North America NK-1 Receptor Antagonists Sales by Country (2027-2032) & (K Units) Table 179. North America NK-1 Receptor Antagonists Sales Price by Country (2021-2026) & (US$/Unit) Table 180. North America NK-1 Receptor Antagonists Sales Price by Country (2027-2032) & (US$/Unit) Table 181. United States NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 182. Canada NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 183. Mexico NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 184. Europe NK-1 Receptor Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 185. Europe NK-1 Receptor Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 186. Europe NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units) Table 187. Europe NK-1 Receptor Antagonists Sales by Type (2027-2032) & (K Units) Table 188. Europe NK-1 Receptor Antagonists Sales Price by Type (2021-2026) & (US$/Unit) Table 189. Europe NK-1 Receptor Antagonists Sales Price by Type (2027-2032) & (US$/Unit) Table 190. Europe NK-1 Receptor Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 191. Europe NK-1 Receptor Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 192. Europe NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units) Table 193. Europe NK-1 Receptor Antagonists Sales by Application (2027-2032) & (K Units) Table 194. Europe NK-1 Receptor Antagonists Sales Price by Application (2021-2026) & (US$/Unit) Table 195. Europe NK-1 Receptor Antagonists Sales Price by Application (2027-2032) & (US$/Unit) Table 196. Europe NK-1 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 197. Europe NK-1 Receptor Antagonists Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 198. Europe NK-1 Receptor Antagonists Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 199. Europe NK-1 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 200. Europe NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units) Table 201. Europe NK-1 Receptor Antagonists Sales by Country (2027-2032) & (K Units) Table 202. Europe NK-1 Receptor Antagonists Sales Price by Country (2021-2026) & (US$/Unit) Table 203. Europe NK-1 Receptor Antagonists Sales Price by Country (2027-2032) & (US$/Unit) Table 204. Germany NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 205. France NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 206. U.K. NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 207. Italy NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 208. Russia NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 209. Spain NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 210. Netherlands NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 211. Switzerland NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 212. Sweden NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 213. Poland NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 214. China NK-1 Receptor Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 215. China NK-1 Receptor Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 216. China NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units) Table 217. China NK-1 Receptor Antagonists Sales by Type (2027-2032) & (K Units) Table 218. China NK-1 Receptor Antagonists Sales Price by Type (2021-2026) & (US$/Unit) Table 219. China NK-1 Receptor Antagonists Sales Price by Type (2027-2032) & (US$/Unit) Table 220. China NK-1 Receptor Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 221. China NK-1 Receptor Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 222. China NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units) Table 223. China NK-1 Receptor Antagonists Sales by Application (2027-2032) & (K Units) Table 224. China NK-1 Receptor Antagonists Sales Price by Application (2021-2026) & (US$/Unit) Table 225. China NK-1 Receptor Antagonists Sales Price by Application (2027-2032) & (US$/Unit) Table 226. Asia NK-1 Receptor Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 227. Asia NK-1 Receptor Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 228. Asia NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units) Table 229. Asia NK-1 Receptor Antagonists Sales by Type (2027-2032) & (K Units) Table 230. Asia NK-1 Receptor Antagonists Sales Price by Type (2021-2026) & (US$/Unit) Table 231. Asia NK-1 Receptor Antagonists Sales Price by Type (2027-2032) & (US$/Unit) Table 232. Asia NK-1 Receptor Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 233. Asia NK-1 Receptor Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 234. Asia NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units) Table 235. Asia NK-1 Receptor Antagonists Sales by Application (2027-2032) & (K Units) Table 236. Asia NK-1 Receptor Antagonists Sales Price by Application (2021-2026) & (US$/Unit) Table 237. Asia NK-1 Receptor Antagonists Sales Price by Application (2027-2032) & (US$/Unit) Table 238. Asia NK-1 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 239. Asia NK-1 Receptor Antagonists Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 240. Asia NK-1 Receptor Antagonists Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 241. Asia NK-1 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 242. Asia NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units) Table 243. Asia NK-1 Receptor Antagonists Sales by Country (2027-2032) & (K Units) Table 244. Asia NK-1 Receptor Antagonists Sales Price by Country (2021-2026) & (US$/Unit) Table 245. Asia NK-1 Receptor Antagonists Sales Price by Country (2027-2032) & (US$/Unit) Table 246. Japan NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 247. South Korea NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 248. India NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 249. Australia NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 250. Taiwan NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 251. Southeast Asia NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 252. SAMEA NK-1 Receptor Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 253. SAMEA NK-1 Receptor Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 254. SAMEA NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units) Table 255. SAMEA NK-1 Receptor Antagonists Sales by Type (2027-2032) & (K Units) Table 256. SAMEA NK-1 Receptor Antagonists Sales Price by Type (2021-2026) & (US$/Unit) Table 257. SAMEA NK-1 Receptor Antagonists Sales Price by Type (2027-2032) & (US$/Unit) Table 258. SAMEA NK-1 Receptor Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 259. SAMEA NK-1 Receptor Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 260. SAMEA NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units) Table 261. SAMEA NK-1 Receptor Antagonists Sales by Application (2027-2032) & (K Units) Table 262. SAMEA NK-1 Receptor Antagonists Sales Price by Application (2021-2026) & (US$/Unit) Table 263. SAMEA NK-1 Receptor Antagonists Sales Price by Application (2027-2032) & (US$/Unit) Table 264. SAMEA NK-1 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 265. SAMEA NK-1 Receptor Antagonists Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 266. SAMEA NK-1 Receptor Antagonists Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 267. SAMEA NK-1 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 268. SAMEA NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units) Table 269. SAMEA NK-1 Receptor Antagonists Sales by Country (2027-2032) & (K Units) Table 270. SAMEA NK-1 Receptor Antagonists Sales Price by Country (2021-2026) & (US$/Unit) Table 271. SAMEA NK-1 Receptor Antagonists Sales Price by Country (2027-2032) & (US$/Unit) Table 272. Brazil NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 273. Argentina NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 274. Chile NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 275. Colombia NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 276. Peru NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 277. Saudi Arabia NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 278. Israel NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 279. UAE NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 280. Turkey NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 281. Iran NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 282. Egypt NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Table 283. Key Raw Materials Table 284. Raw Materials Key Suppliers Table 285. NK-1 Receptor Antagonists Distributors List Table 286. NK-1 Receptor Antagonists Customers List Table 287. Research Programs/Design for This Report Table 288. Authors List of This Report Table 289. Secondary Sources Table 290. Primary Sources List of Figures Figure 1. NK-1 Receptor Antagonists Image Figure 2. Global NK-1 Receptor Antagonists Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NK-1 Receptor Antagonists Market Size Share 2021 VS 2025 VS 2032 Figure 4. Netupitant Image Figure 5. Maropitant Image Figure 6. Rolapitant Image Figure 7. Fosaprepitant Image Figure 8. Aprepitant Image Figure 9. Other Image Figure 10. Global NK-1 Receptor Antagonists Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global NK-1 Receptor Antagonists Market Size Share 2021 VS 2025 VS 2032 Figure 12. Chemotherapy-induced Nausea and Vomiting (CINV) Image Figure 13. Postoperative Nausea and Vomiting (PONV) Image Figure 14. Other Image Figure 15. Global NK-1 Receptor Antagonists Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global NK-1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Figure 17. Global NK-1 Receptor Antagonists Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global NK-1 Receptor Antagonists Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global NK-1 Receptor Antagonists Revenue Market Share by Region (2021-2032) Figure 20. Global NK-1 Receptor Antagonists Sales (2021-2032) & (K Units) Figure 21. Global NK-1 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 22. Global NK-1 Receptor Antagonists Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico NK-1 Receptor Antagonists Sales YoY (2021-2032) & (K Units) Figure 24. Europe NK-1 Receptor Antagonists Sales YoY (2021-2032) & (K Units) Figure 25. China NK-1 Receptor Antagonists Sales YoY (2021-2032) & (K Units) Figure 26. Asia (Excluding China) NK-1 Receptor Antagonists Sales YoY (2021-2032) & (K Units) Figure 27. South America, Middle East and Africa NK-1 Receptor Antagonists Sales YoY (2021-2032) & (K Units) Figure 28. Global NK-1 Receptor Antagonists Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global NK-1 Receptor Antagonists Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global NK-1 Receptor Antagonists Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global NK-1 Receptor Antagonists Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2021-2032) Figure 34. Global NK-1 Receptor Antagonists Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 35. Global NK-1 Receptor Antagonists Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global NK-1 Receptor Antagonists Sales Market Share by Type (2021-2032) Figure 37. Global NK-1 Receptor Antagonists Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global NK-1 Receptor Antagonists Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global NK-1 Receptor Antagonists Revenue Market Share by Application (2021-2032) Figure 40. Global NK-1 Receptor Antagonists Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 41. Global NK-1 Receptor Antagonists Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global NK-1 Receptor Antagonists Sales Market Share by Application (2021-2032) Figure 43. North America NK-1 Receptor Antagonists Revenue Share by Type (2021-2032) Figure 44. North America NK-1 Receptor Antagonists Sales Share by Type (2021-2032) Figure 45. North America NK-1 Receptor Antagonists Revenue Share by Application (2021-2032) Figure 46. North America NK-1 Receptor Antagonists Sales Share by Application (2021-2032) Figure 47. North America NK-1 Receptor Antagonists Revenue Share by Country (2021-2032) Figure 48. North America NK-1 Receptor Antagonists Sales Share by Country (2021-2032) Figure 49. Europe NK-1 Receptor Antagonists Revenue Share by Type (2021-2032) Figure 50. Europe NK-1 Receptor Antagonists Sales Share by Type (2021-2032) Figure 51. Europe NK-1 Receptor Antagonists Revenue Share by Application (2021-2032) Figure 52. Europe NK-1 Receptor Antagonists Sales Share by Application (2021-2032) Figure 53. Europe NK-1 Receptor Antagonists Revenue Share by Country (2021-2032) Figure 54. Europe NK-1 Receptor Antagonists Sales Share by Country (2021-2032) Figure 55. China NK-1 Receptor Antagonists Revenue Share by Type (2021-2032) Figure 56. China NK-1 Receptor Antagonists Sales Share by Type (2021-2032) Figure 57. China NK-1 Receptor Antagonists Revenue Share by Application (2021-2032) Figure 58. China NK-1 Receptor Antagonists Sales Share by Application (2021-2032) Figure 59. Asia NK-1 Receptor Antagonists Revenue Share by Type (2021-2032) Figure 60. Asia NK-1 Receptor Antagonists Sales Share by Type (2021-2032) Figure 61. Asia NK-1 Receptor Antagonists Revenue Share by Application (2021-2032) Figure 62. Asia NK-1 Receptor Antagonists Sales Share by Application (2021-2032) Figure 63. Asia NK-1 Receptor Antagonists Revenue Share by Country (2021-2032) Figure 64. Asia NK-1 Receptor Antagonists Sales Share by Country (2021-2032) Figure 65. SAMEA NK-1 Receptor Antagonists Revenue Share by Type (2021-2032) Figure 66. SAMEA NK-1 Receptor Antagonists Sales Share by Type (2021-2032) Figure 67. SAMEA NK-1 Receptor Antagonists Revenue Share by Application (2021-2032) Figure 68. SAMEA NK-1 Receptor Antagonists Sales Share by Application (2021-2032) Figure 69. SAMEA NK-1 Receptor Antagonists Revenue Share by Country (2021-2032) Figure 70. SAMEA NK-1 Receptor Antagonists Sales Share by Country (2021-2032) Figure 71. NK-1 Receptor Antagonists Value Chain Figure 72. Manufacturing Cost Structure Figure 73. NK-1 Receptor Antagonists Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Netupitant
  • Maropitant
  • Rolapitant
  • Fosaprepitant
  • Aprepitant
  • Other
Applications
  • Chemotherapy-induced Nausea and Vomiting (CINV)
  • Postoperative Nausea and Vomiting (PONV)
  • Other
Companies covered
  • Dr. Reddy's Laboratories
  • Eugia Pharma
  • Fresenius Kabi
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • Lupin
  • MSN
  • Mylan
  • Steriscience
  • TerSera Therapeutics
  • Teva
  • Torrent Pharmaceuticals
  • Beijing Sihuan Pharmaceutical
  • Hansoh Pharma
  • Merck
  • Qilu Pharmaceutical
  • Sandoz
  • Yichang Humanwell Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 NK-1 Receptor Antagonists Market by Type
  3. 1.2.1 Global NK-1 Receptor Antagonists Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Netupitant
  5. 1.2.3 Maropitant
  6. 1.2.4 Rolapitant
  7. 1.2.5 Fosaprepitant
  8. 1.2.6 Aprepitant
  9. 1.2.7 Other
  10. 1.3 NK-1 Receptor Antagonists Market by Application
  11. 1.3.1 Global NK-1 Receptor Antagonists Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Chemotherapy-induced Nausea and Vomiting (CINV)
  13. 1.3.3 Postoperative Nausea and Vomiting (PONV)
  14. 1.3.4 Other
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 NK-1 Receptor Antagonists Market Dynamics
  1. 2.1 NK-1 Receptor Antagonists Industry Trends
  2. 2.2 NK-1 Receptor Antagonists Industry Drivers
  3. 2.3 NK-1 Receptor Antagonists Industry Opportunities and Challenges
  4. 2.4 NK-1 Receptor Antagonists Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global NK-1 Receptor Antagonists Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global NK-1 Receptor Antagonists Revenue by Region
  3. 3.2.1 Global NK-1 Receptor Antagonists Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global NK-1 Receptor Antagonists Revenue by Region (2021-2026)
  5. 3.2.3 Global NK-1 Receptor Antagonists Revenue by Region (2027-2032)
  6. 3.2.4 Global NK-1 Receptor Antagonists Revenue Market Share by Region (2021-2032)
  7. 3.3 Global NK-1 Receptor Antagonists Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global NK-1 Receptor Antagonists Sales by Region
  9. 3.4.1 Global NK-1 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global NK-1 Receptor Antagonists Sales by Region (2021-2026)
  11. 3.4.3 Global NK-1 Receptor Antagonists Sales by Region (2027-2032)
  12. 3.4.4 Global NK-1 Receptor Antagonists Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global NK-1 Receptor Antagonists Revenue by Manufacturers
  2. 4.1.1 Global NK-1 Receptor Antagonists Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global NK-1 Receptor Antagonists Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global NK-1 Receptor Antagonists Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global NK-1 Receptor Antagonists Sales by Manufacturers
  6. 4.2.1 Global NK-1 Receptor Antagonists Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global NK-1 Receptor Antagonists Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global NK-1 Receptor Antagonists Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global NK-1 Receptor Antagonists Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global NK-1 Receptor Antagonists Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global NK-1 Receptor Antagonists Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global NK-1 Receptor Antagonists Manufacturers, Product Type & Application
  13. 4.7 Global NK-1 Receptor Antagonists Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global NK-1 Receptor Antagonists Market CR5 and HHI
  16. 4.8.2 2025 NK-1 Receptor Antagonists Tier 1, Tier 2, and Tier 3
5 NK-1 Receptor Antagonists Market by Type
  1. 5.1 Global NK-1 Receptor Antagonists Revenue by Type
  2. 5.1.1 Global NK-1 Receptor Antagonists Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global NK-1 Receptor Antagonists Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global NK-1 Receptor Antagonists Revenue Market Share by Type (2021-2032)
  5. 5.2 Global NK-1 Receptor Antagonists Sales by Type
  6. 5.2.1 Global NK-1 Receptor Antagonists Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global NK-1 Receptor Antagonists Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global NK-1 Receptor Antagonists Sales Market Share by Type (2021-2032)
  9. 5.3 Global NK-1 Receptor Antagonists Price by Type
6 NK-1 Receptor Antagonists Market by Application
  1. 6.1 Global NK-1 Receptor Antagonists Revenue by Application
  2. 6.1.1 Global NK-1 Receptor Antagonists Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global NK-1 Receptor Antagonists Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global NK-1 Receptor Antagonists Revenue Market Share by Application (2021-2032)
  5. 6.2 Global NK-1 Receptor Antagonists Sales by Application
  6. 6.2.1 Global NK-1 Receptor Antagonists Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global NK-1 Receptor Antagonists Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global NK-1 Receptor Antagonists Sales Market Share by Application (2021-2032)
  9. 6.3 Global NK-1 Receptor Antagonists Price by Application
7 Company Profiles
  1. 7.1 Dr. Reddy's Laboratories
  2. 7.1.1 Dr. Reddy's Laboratories Company Information
  3. 7.1.2 Dr. Reddy's Laboratories Business Overview
  4. 7.1.3 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolio
  6. 7.1.5 Dr. Reddy's Laboratories Recent Developments
  7. 7.2 Eugia Pharma
  8. 7.2.1 Eugia Pharma Company Information
  9. 7.2.2 Eugia Pharma Business Overview
  10. 7.2.3 Eugia Pharma NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Eugia Pharma NK-1 Receptor Antagonists Product Portfolio
  12. 7.2.5 Eugia Pharma Recent Developments
  13. 7.3 Fresenius Kabi
  14. 7.3.1 Fresenius Kabi Company Information
  15. 7.3.2 Fresenius Kabi Business Overview
  16. 7.3.3 Fresenius Kabi NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Fresenius Kabi NK-1 Receptor Antagonists Product Portfolio
  18. 7.3.5 Fresenius Kabi Recent Developments
  19. 7.4 Glenmark
  20. 7.4.1 Glenmark Company Information
  21. 7.4.2 Glenmark Business Overview
  22. 7.4.3 Glenmark NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Glenmark NK-1 Receptor Antagonists Product Portfolio
  24. 7.4.5 Glenmark Recent Developments
  25. 7.5 Helsinn Healthcare
  26. 7.5.1 Helsinn Healthcare Company Information
  27. 7.5.2 Helsinn Healthcare Business Overview
  28. 7.5.3 Helsinn Healthcare NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolio
  30. 7.5.5 Helsinn Healthcare Recent Developments
  31. 7.6 Heron Therapeutics
  32. 7.6.1 Heron Therapeutics Company Information
  33. 7.6.2 Heron Therapeutics Business Overview
  34. 7.6.3 Heron Therapeutics NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Heron Therapeutics NK-1 Receptor Antagonists Product Portfolio
  36. 7.6.5 Heron Therapeutics Recent Developments
  37. 7.7 Lupin
  38. 7.7.1 Lupin Company Information
  39. 7.7.2 Lupin Business Overview
  40. 7.7.3 Lupin NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Lupin NK-1 Receptor Antagonists Product Portfolio
  42. 7.7.5 Lupin Recent Developments
  43. 7.8 MSN
  44. 7.8.1 MSN Company Information
  45. 7.8.2 MSN Business Overview
  46. 7.8.3 MSN NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 MSN NK-1 Receptor Antagonists Product Portfolio
  48. 7.8.5 MSN Recent Developments
  49. 7.9 Mylan
  50. 7.9.1 Mylan Company Information
  51. 7.9.2 Mylan Business Overview
  52. 7.9.3 Mylan NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Mylan NK-1 Receptor Antagonists Product Portfolio
  54. 7.9.5 Mylan Recent Developments
  55. 7.10 Steriscience
  56. 7.10.1 Steriscience Company Information
  57. 7.10.2 Steriscience Business Overview
  58. 7.10.3 Steriscience NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Steriscience NK-1 Receptor Antagonists Product Portfolio
  60. 7.10.5 Steriscience Recent Developments
  61. 7.11 TerSera Therapeutics
  62. 7.11.1 TerSera Therapeutics Company Information
  63. 7.11.2 TerSera Therapeutics Business Overview
  64. 7.11.3 TerSera Therapeutics NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolio
  66. 7.11.5 TerSera Therapeutics Recent Developments
  67. 7.12 Teva
  68. 7.12.1 Teva Company Information
  69. 7.12.2 Teva Business Overview
  70. 7.12.3 Teva NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Teva NK-1 Receptor Antagonists Product Portfolio
  72. 7.12.5 Teva Recent Developments
  73. 7.13 Torrent Pharmaceuticals
  74. 7.13.1 Torrent Pharmaceuticals Company Information
  75. 7.13.2 Torrent Pharmaceuticals Business Overview
  76. 7.13.3 Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolio
  78. 7.13.5 Torrent Pharmaceuticals Recent Developments
  79. 7.14 Beijing Sihuan Pharmaceutical
  80. 7.14.1 Beijing Sihuan Pharmaceutical Company Information
  81. 7.14.2 Beijing Sihuan Pharmaceutical Business Overview
  82. 7.14.3 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  84. 7.14.5 Beijing Sihuan Pharmaceutical Recent Developments
  85. 7.15 Hansoh Pharma
  86. 7.15.1 Hansoh Pharma Company Information
  87. 7.15.2 Hansoh Pharma Business Overview
  88. 7.15.3 Hansoh Pharma NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Hansoh Pharma NK-1 Receptor Antagonists Product Portfolio
  90. 7.15.5 Hansoh Pharma Recent Developments
  91. 7.16 Merck
  92. 7.16.1 Merck Company Information
  93. 7.16.2 Merck Business Overview
  94. 7.16.3 Merck NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Merck NK-1 Receptor Antagonists Product Portfolio
  96. 7.16.5 Merck Recent Developments
  97. 7.17 Qilu Pharmaceutical
  98. 7.17.1 Qilu Pharmaceutical Company Information
  99. 7.17.2 Qilu Pharmaceutical Business Overview
  100. 7.17.3 Qilu Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  102. 7.17.5 Qilu Pharmaceutical Recent Developments
  103. 7.18 Sandoz
  104. 7.18.1 Sandoz Company Information
  105. 7.18.2 Sandoz Business Overview
  106. 7.18.3 Sandoz NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Sandoz NK-1 Receptor Antagonists Product Portfolio
  108. 7.18.5 Sandoz Recent Developments
  109. 7.19 Yichang Humanwell Pharmaceutical
  110. 7.19.1 Yichang Humanwell Pharmaceutical Company Information
  111. 7.19.2 Yichang Humanwell Pharmaceutical Business Overview
  112. 7.19.3 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  114. 7.19.5 Yichang Humanwell Pharmaceutical Recent Developments
  115. 7.20 Chia Tai Tianqing Pharmaceutical
  116. 7.20.1 Chia Tai Tianqing Pharmaceutical Company Information
  117. 7.20.2 Chia Tai Tianqing Pharmaceutical Business Overview
  118. 7.20.3 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  120. 7.20.5 Chia Tai Tianqing Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America NK-1 Receptor Antagonists Market Size by Type
  2. 8.1.1 North America NK-1 Receptor Antagonists Revenue by Type (2021-2032)
  3. 8.1.2 North America NK-1 Receptor Antagonists Sales by Type (2021-2032)
  4. 8.1.3 North America NK-1 Receptor Antagonists Price by Type (2021-2032)
  5. 8.2 North America NK-1 Receptor Antagonists Market Size by Application
  6. 8.2.1 North America NK-1 Receptor Antagonists Revenue by Application (2021-2032)
  7. 8.2.2 North America NK-1 Receptor Antagonists Sales by Application (2021-2032)
  8. 8.2.3 North America NK-1 Receptor Antagonists Price by Application (2021-2032)
  9. 8.3 North America NK-1 Receptor Antagonists Market Size by Country
  10. 8.3.1 North America NK-1 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America NK-1 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America NK-1 Receptor Antagonists Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe NK-1 Receptor Antagonists Market Size by Type
  2. 9.1.1 Europe NK-1 Receptor Antagonists Revenue by Type (2021-2032)
  3. 9.1.2 Europe NK-1 Receptor Antagonists Sales by Type (2021-2032)
  4. 9.1.3 Europe NK-1 Receptor Antagonists Price by Type (2021-2032)
  5. 9.2 Europe NK-1 Receptor Antagonists Market Size by Application
  6. 9.2.1 Europe NK-1 Receptor Antagonists Revenue by Application (2021-2032)
  7. 9.2.2 Europe NK-1 Receptor Antagonists Sales by Application (2021-2032)
  8. 9.2.3 Europe NK-1 Receptor Antagonists Price by Application (2021-2032)
  9. 9.3 Europe NK-1 Receptor Antagonists Market Size by Country
  10. 9.3.1 Europe NK-1 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe NK-1 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe NK-1 Receptor Antagonists Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China NK-1 Receptor Antagonists Market Size by Type
  2. 10.1.1 China NK-1 Receptor Antagonists Revenue by Type (2021-2032)
  3. 10.1.2 China NK-1 Receptor Antagonists Sales by Type (2021-2032)
  4. 10.1.3 China NK-1 Receptor Antagonists Price by Type (2021-2032)
  5. 10.2 China NK-1 Receptor Antagonists Market Size by Application
  6. 10.2.1 China NK-1 Receptor Antagonists Revenue by Application (2021-2032)
  7. 10.2.2 China NK-1 Receptor Antagonists Sales by Application (2021-2032)
  8. 10.2.3 China NK-1 Receptor Antagonists Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia NK-1 Receptor Antagonists Market Size by Type
  2. 11.1.1 Asia NK-1 Receptor Antagonists Revenue by Type (2021-2032)
  3. 11.1.2 Asia NK-1 Receptor Antagonists Sales by Type (2021-2032)
  4. 11.1.3 Asia NK-1 Receptor Antagonists Price by Type (2021-2032)
  5. 11.2 Asia NK-1 Receptor Antagonists Market Size by Application
  6. 11.2.1 Asia NK-1 Receptor Antagonists Revenue by Application (2021-2032)
  7. 11.2.2 Asia NK-1 Receptor Antagonists Sales by Application (2021-2032)
  8. 11.2.3 Asia NK-1 Receptor Antagonists Price by Application (2021-2032)
  9. 11.3 Asia NK-1 Receptor Antagonists Market Size by Country
  10. 11.3.1 Asia NK-1 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia NK-1 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia NK-1 Receptor Antagonists Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA NK-1 Receptor Antagonists Market Size by Type
  2. 12.1.1 SAMEA NK-1 Receptor Antagonists Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA NK-1 Receptor Antagonists Sales by Type (2021-2032)
  4. 12.1.3 SAMEA NK-1 Receptor Antagonists Price by Type (2021-2032)
  5. 12.2 SAMEA NK-1 Receptor Antagonists Market Size by Application
  6. 12.2.1 SAMEA NK-1 Receptor Antagonists Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA NK-1 Receptor Antagonists Sales by Application (2021-2032)
  8. 12.2.3 SAMEA NK-1 Receptor Antagonists Price by Application (2021-2032)
  9. 12.3 SAMEA NK-1 Receptor Antagonists Market Size by Country
  10. 12.3.1 SAMEA NK-1 Receptor Antagonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA NK-1 Receptor Antagonists Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA NK-1 Receptor Antagonists Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 NK-1 Receptor Antagonists Value Chain Analysis
  2. 13.1.1 NK-1 Receptor Antagonists Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 NK-1 Receptor Antagonists Production Mode & Process
  6. 13.2 NK-1 Receptor Antagonists Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 NK-1 Receptor Antagonists Distributors
  9. 13.2.3 NK-1 Receptor Antagonists Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst